Author pages are created from data sourced from our academic publisher partnerships and public sources.
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
BACKGROUND Seroprevalence data suggest that a third of the world's population has been infected with the hepatitis E virus. Our aim was to assess efficacy and safety of a recombinant hepatitis E… Expand
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Summary Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and… Expand
A novel influenza A (H1N1) vaccine in various age groups.
- F. Zhu, H. Wang, +17 authors Jing-shan Zheng
- The New England journal of medicine
- 17 December 2009
BACKGROUND There is an urgent need for a vaccine that is effective against the 2009 pandemic influenza A (H1N1) virus. METHODS A split-virus, inactivated candidate vaccine against the 2009 H1N1… Expand
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
BACKGROUND A vaccine for enterovirus 71 (EV71) is needed to address the high burden of disease associated with infection. We assessed the efficacy, safety, immunogenicity, antibody persistence, and… Expand
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.
BACKGROUND Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease or herpangina worldwide. This phase 3 trial was designed to evaluate the efficacy,… Expand
Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus.
Influenza A (H7N9) virus has been causing human infections in China since February 2013, raising serious concerns of potential pandemics. Previous studies demonstrate that human infection is directly… Expand
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Background This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to… Expand
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1…
BACKGROUND Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant… Expand
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
Abstract Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated the serum cytokine and chemokine… Expand
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation
Objective To determine whether the novel avian influenza H7N9 virus can transmit from person to person and its efficiency. Design Epidemiological investigations conducted after a family cluster of… Expand